Skip to main content
Clinical Trials/NL-OMON28450
NL-OMON28450
Recruiting
N/A

A cluster Randomised Controlled Trial of the effectiveness, usability and acceptability of a smart inhaler programme in asthma patients: the ACCEPTANCE study

eiden University Medical Center0 sites242 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
eiden University Medical Center
Enrollment
242
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
eiden University Medical Center

Eligibility Criteria

Inclusion Criteria

  • 1\. Doctor\-diagnosed asthma (when recruited via general practices or public channels), self\-reported asthma diagnosis (when recruited via pharmacies \- asthma diagnosis will be confirmed by GP at study end (T12\))
  • 2\. Partially controlled or uncontrolled asthma, defined as an ACQ\-5 score \=0\.75 at the first visit T\-1
  • 3\. Use of Symbicort® Turbuhaler® as maintenance therapy for at least eight weeks before entering the run\-in period
  • 4\. Being non\-adherent during the run\-in period, defined as an adherence rate of below 80% over the third and fourth week of the run\-in period. Adherence is defined as the number of adherent days as a proportion of the total number of days during the third and fourth week of the run\-in period.
  • 5\. In possession of a smartphone
  • 6\. Written informed consent

Exclusion Criteria

  • 1\. Age \< 18 years
  • 2\. Use of SMART regimen (Symbicort Maintenance And Reliever Therapy) by taking Symbicort as reliever in response to symptoms
  • 3\. Change in inhaled corticosteroids (ICS) dose in the 4 weeks prior to the run\-in period
  • 4\. Use of systemic corticosteroids in the 4 weeks prior to the run\-in period, including maintenance therapy
  • 5\. Current use of biologics, including anti\-IL\-5 (mepolizumab, reslizumab, benralizumab) or anti\-IgE (omalizumab)
  • 6\. Diagnosis of COPD, interstitial lung diseases, bronchiectasis or other significant respiratory condition
  • 7\. Malignancy with life expectancy \< 1 year
  • 8\. Pregnancy
  • 9\. Inability to understand Dutch
  • 10\. Any other condition which, at the GPs and/or investigator’s discretion, is believed may present a safety risk or impact the study results

Outcomes

Primary Outcomes

Not specified

Similar Trials